Effect of organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphism on the single- and multiple-dose pharmacokinetics of enalapril in healthy Chinese adult men

Clinical Therapeutics

Volumn 33, Issue 5, 2011, Pages 655-663

  Tian, Lei ^a   Liu, Hong ^a   Xie, Shuang ^a   Jiang, Juanjuan ^a   Han, Lulu ^a   Huang, Yiling ^a   Li, Yishi ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

Enalapril; Enalaprilat; OATP1B1 polymorphism; Pharmacokinetics

Indexed keywords

ENALAPRIL; ENALAPRILAT; ORGANIC ANION TRANSPORTER 2;

ADULT; ALLELE; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CHINESE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; ELECTROCARDIOGRAM; GENOTYPE; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; ORTHOSTATIC HYPOTENSION; PHARMACOGENETICS; PLASMA CONCENTRATION-TIME CURVE; SIDE EFFECT; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; TIME TO MAXIMUM PLASMA CONCENTRATION; VITAL SIGN;

ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; AREA UNDER CURVE; BASE SEQUENCE; CHINA; DNA PRIMERS; ENALAPRIL; HUMANS; MALE; ORGANIC ANION TRANSPORTERS; POLYMORPHISM, SINGLE NUCLEOTIDE; REFERENCE VALUES;

EID: 79958752724     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.04.018     Document Type: Article

References (23)

1. Ghods A.J., Ossareh S. Beneficial effect of enalapril on slowing the progression of chronic renal allograft dysfunction. Transplant Proc 2003, 35:2641-2642.
2. Niopas I., Daftsios A.C., Nikolaidis N. Bioequivalence study of two brands of enalapril tablets after single oral administration to healthy volunteers. Int J Clin Pharmacol Ther 2003, 41:226-230.
3. MacFadyen R.J., Meredith P.A., Elliott H.L. Enalapril clinical pharmacokinetics and pharmacokinetic-pharmacodynamic relationships. Clin Pharmacokinet 1993, 25:274-282.
4. König J., Cui Y., Nies A.T., et al. A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am J Physiol Gastrointest Liver Physiol 2000, 278:G156-G164.
5. Mwinyi J., Johne A., Bauer S., et al. Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin Pharmacol Ther 2004, 75:415-421.
6. Pasanen M.K., Neuvonen M., Neuvonen P.J., Niemi M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 2007, 82:726-733.
7. Nakagomi-Hagihara R., Nakai D., Kawai K., et al. OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker. Drug Metab Dispos 2006, 34:862-869.
8. Yamashiro W., Maeda K., Hirouchi M., et al. Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans. Drug Metab Dispos 2006, 34:1247-1254.
9. Liu L., Cui Y., Chung A.Y., et al. Vectorial transport of enalapril by Oatp1a1/Mrp2 and OATP1B1 and OATP1B3/MRP2 in rat and human livers. J Pharmacol Exp Ther 2006, 318:395-402.
10. Kim S.-R., Saito Y., Sai K., et al. Genetic variations and frequencies of major haplotypes in SLCO1B1 encoding the transporter OATP1B1 in Japanese subjects: SLCO1B1*17 is more prevalent than *15. Drug Metab Pharmacokinet 2007, 22:456-461.
11. Pasanen M.K., Neuvonen M., Neuvonen P.J., Niemi M. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 2006, 16:873-879.
12. Niemi M., Backman J.T., Kajosaari L.I., et al. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther 2005, 77:468-478.
13. Guideline for Good Clinical Practice European Medicines Agency, ICH Topic E6 (R1), Accessed August 15, 2008. http://www.ema.europa.eu/pdfs/human/ich/013595en.pdf.
14. Ethical Principles for Medical Research Involving Human Subjects World Medical Association Declaration of Helsinki, Accessed August 15, 2008. http://www.wma.net/en/30publications/10policies/b3/.
15. Gu Q., Chen X.Y., Zhong D.F., et al. Simultaneous determination of enalapril and enalaprilat in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B 2004, 813:337-342.
16. Nishizato Y., Ieiri I., Suzuki H., et al. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther 2003, 73:554-565.
17. Choi J.H., Lee M.G., Cho J.-Y., et al. Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans. Clin Pharmacol Ther 2008, 83:251-257.
18. Maeda K., Ieiri I., Yasuda K., et al. Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. Clin Pharmacol Ther 2006, 79:427-439.
19. Ishizuka H., Konno K., Naganuma H., et al. Temocaprilat, a novel angiotensin converting enzyme inhibitor, is excreted in bile via an ATP dependent active transporter (cMOAT) that is deficient in Eisai hyperbilirubinemic mutant rats (EHBR). J Pharmacol Exp Ther 1997, 280:1304-1311.
20. Tirona R.G., Leake B.F., Wolkoff A.W., et al. Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther 2003, 304:223-228.
21. Kameyama Y., Yamashita K., Kobayashi K., et al. Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15 +C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics 2005, 15:513-522.
22. Iwai M., Suzuki H., Ieiri I., et al. Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C). Pharmacogenetics 2004, 14:749-757.
23. Ishizaki T., Baba T., Murabayashi S., et al. Effect of cimetidine on the pharmacokinetics and pharmacodynamics of enalapril in normal volunteers. J Cardiovasc Pharmacol 1988, 12. 521-519.